Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00990236 · ClinicalTrials.gov registry record · NA
Thrombelastography Based Dosing of Enoxaparin
A NA study of Thromboembolic Complications, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- NA
- Development phase
- 185
- Enrollment target
- 3
- Study locations
NCT00990236 is a NA study of Thromboembolic Complications that has completed, run by Oregon Health and Science University. The registered enrollment target is 185 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT00990236, a NA study of Thromboembolic Complications, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- NA
- Development phase
- 185 participants
- Enrollment target
- 3
- Study locations
Study Summary
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs. Recent data suggest that a standard dose of Lovenox may not fully prevent the development of these clots especially in critically ill or obese patients. Routine enoxaparin dosing can also result in bleeding complications. Thrombelastography (TEG®) can be used to measure how blood clots. The purposes of this study are: * to learn if the TEG® can better guide physicians in prescribing an effective dose of Lovenox compared to standard doses recommended by the drug company in preventing blood clots from developing in the legs and lungs, and * to compare the development of blood clots in patients receiving the standard dose of enoxaparin compared to patients receiving a TEG® guided dose of enoxaparin. * to determine if TEG guided dosing results in decreased bleeding complications compared to standard dosing.
Conditions Studied
Interventions
- DRUG Enoxaparin dose adjusted Lovenox based on TEG
- DRUG Enoxaparin 30 mg BID
Study Locations (3)
Oregon
- Oregon Health & Science University - Portland
Texas
- University of Texas Health Science Center at Houston - Houston
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00990236
The ClinicalTrials.gov registry entry for NCT00990236 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thromboembolic Complications appearing as the primary indexed condition, and to 2 interventions - of which Enoxaparin dose adjusted Lovenox based on TEG is the first listed.
NCT00990236 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Oregon, Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT00990236 about?
NCT00990236 is a clinical study titled "Thrombelastography Based Dosing of Enoxaparin". The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs. Recent data suggest that a standard dose of Lovenox may not fully prevent the developme...
What is the current status of trial NCT00990236?
This trial is currently completed. It is a NA study. The enrollment target is 185 participants. The study started on 2009-09. Estimated completion is 2015-03.
What conditions does trial NCT00990236 study?
This clinical trial studies the following conditions: Thromboembolic Complications.
What interventions are being tested in trial NCT00990236?
The interventions under investigation include: Enoxaparin dose adjusted Lovenox based on TEG (DRUG), Enoxaparin 30 mg BID (DRUG).
Who is sponsoring clinical trial NCT00990236?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00990236 being conducted?
This trial has 3 study locations across Oregon, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.